L3VLUP
ProSign in

GSK · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GSKJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GSK
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterGSKJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 2021none listed holders, n.a.40 holders, $24.1bn
Q4 2021none listed holders, n.a.33 holders, $25.2bn
Q1 2022none listed holders, n.a.35 holders, $28.2bn
Q2 20221 holders, $19m33 holders, $26.9bn
Q3 202218 holders, $3.9bn36 holders, $25.4bn
Q4 202218 holders, $4.9bn35 holders, $27.6bn
Q1 202313 holders, $4.4bn42 holders, $24.5bn
Q2 202313 holders, $4.3bn38 holders, $25.0bn
Q3 202316 holders, $4.5bn37 holders, $18.9bn
Q4 202313 holders, $4.5bn31 holders, $19.0bn
Q1 202413 holders, $5.3bn32 holders, $19.7bn
Q2 202410 holders, $4.6bn35 holders, $20.4bn
Q3 202410 holders, $4.9bn28 holders, $22.3bn
Q4 202413 holders, $4.9bn37 holders, $20.4bn
Q1 202511 holders, $6.3bn32 holders, $20.5bn
Q2 202510 holders, $6.2bn31 holders, $18.4bn
Q3 202511 holders, $7.5bn32 holders, $23.7bn
Q4 202511 holders, $8.8bn29 holders, $27.8bn
Q1 20269 holders, $9.1bn34 holders, $35.6bn
Q2 202611 holders, $7.5bn33 holders, $39.1bn
GSK

GSK PLC

Holders
9
Reported value
$9.1bn
Buyers
9
Sellers
19

Breadth -10 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
34
Reported value
$35.6bn
Buyers
21
Sellers
18

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GSK (1)

Holocene Advisors LP

Only JNJ (26)

AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Farallon Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, Soros Fund Management LLC, Squarepoint Ops LLC, Verition Fund Management LLC, Winton Group Ltd, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →